静脉溶栓治疗轻型急性缺血性卒中的随机对照试验荟萃分析
该荟萃分析纳入4项仅针对NIHSS≤5分轻型卒中患者的随机对照试验(N=3,364),比较静脉溶栓与非溶栓标准治疗。主要分析显示静脉溶栓未显著提高90天极佳功能恢复(mRS 0-1)的比值比(OR 0.85,95%CI 0.70-1.03),但显著降低90天功能独立(mRS 0-2)的比值比(OR 0.71,95%CI 0.55-0.91),并显著增加症状性颅内出血(OR 5.22,95%CI 1.76-15.48)和90天死亡(OR 2.40,95%CI 1.23-4.67)的比值比。
要点
- 静脉溶栓未显著改善轻型卒中90天极佳功能恢复(mRS 0-1)。
- 静脉溶栓显著增加症状性颅内出血和90天死亡风险。
- 多数纳入患者为非致残性轻型卒中,致残性轻型卒中证据不足。
核心结论
- 静脉溶栓未改善轻型卒中患者的功能结局,且与更高的症状性颅内出血和90天死亡比值比相关。
研究设计与样本
- 系统检索并纳入仅 enrolling 轻型卒中(NIHSS≤5分)的随机对照试验,主要分析纳入4项RCT共3,364例患者(年龄范围56-80岁)。
- 次要分析纳入早期RCT中轻型卒中患者的post hoc和亚组数据;研究注册于PROSPERO(CRD42024621714)。
主要发现
- 主要分析中,静脉溶栓 vs 非溶栓标准治疗90天极佳功能恢复(mRS 0-1)的OR为0.85(95%CI 0.70-1.03),无显著差异。
- 静脉溶栓显著降低90天功能独立(mRS 0-2)的比值比(OR 0.71,95%CI 0.55-0.91)。
- 静脉溶栓显著增加症状性颅内出血(OR 5.22,95%CI 1.76-15.48)和90天死亡(OR 2.40,95%CI 1.23-4.67)的比值比。
- 亚组分析显示,致残性症状组(OR 0.84,95%CI 0.38-1.88)和非致残性症状组(OR 0.82,95%CI 0.66-1.03)的极佳功能恢复OR均无显著差异。
- 汇总分析(纳入非重叠亚组和post hoc数据)结果与主要分析一致。
关键数值与推荐
- 轻型卒中定义为NIHSS评分≤5分。
- 主要结局为90天极佳功能恢复,定义为mRS评分0-1分。
- 次要结局包括90天功能独立(mRS 0-2分)及安全终点(90天死亡、复发性卒中、症状性颅内出血、任何颅内出血)。
临床怎么用
- 对于以非致残性症状为主的轻型卒中患者,静脉溶栓可能不改善功能结局且增加出血和死亡风险。
- 临床决策需个体化权衡静脉溶栓的获益与风险,尤其需关注症状性颅内出血和死亡风险。
- 对轻度致残性症状的轻型卒中患者,现有证据不足,需进一步研究。
局限性
- 多数纳入患者为非致残性轻型卒中,结果外推至致残性轻型卒中受限。
- 次要分析纳入post hoc和亚组数据,可能存在选择偏倚。
- 未报告各RCT的具体样本量、剂量、P值等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The therapeutic efficacy and safety of IV thrombolysis (IVT) for patients with minor strokes remain a subject of significant debate and uncertainty. This meta-analysis aimed to assess the comparative effectiveness and safety of IVT vs nonthrombolytic standard of care (NT-SC) in minor strokes, focusing exclusively on data from randomized controlled trials (RCTs). METHODS: A comprehensive literature search was conducted to identify RCTs evaluating IVT in minor stroke, defined as a NIH Stroke Scale (NIHSS) score ≤5. The primary outcome was excellent functional recovery, defined as a modified Rankin Scale (mRS) score of 0-1 at 90 days. Secondary outcomes included functional independence (mRS 0-2 at 90 days) and safety end points, including 90-day mortality, recurrent stroke, symptomatic intracranial hemorrhage (sICH), and any ICH. The study was registered with PROSPERO (CRD42024621714). RESULTS: The primary analysis included data from 4 RCTs that exclusively enrolled patients with minor stroke (N = 3,364; age range: 56-80 years). Secondary analyses incorporated post hoc and subgroup data on patients with minor stroke from earlier RCTs. In the primary analysis, IVT was not significantly associated with higher odds of excellent functional recovery at 90 days compared with NT-SC (mRS 0-1; odds ratio [OR] 0.85, 95% CI 0.70-1.03). IVT was significantly associated with lower odds of achieving 90-day functional independence (mRS 0-2; OR 0.71, 95% CI 0.55-0.91) and higher odds of both sICH (OR 5.22, 95% CI 1.76-15.48) and 90-day mortality (OR 2.40, 95% CI 1.23-4.67) compared with NT-SC. Subgroup analysis showed a nonsignificant association of IVT with odds of excellent functional recovery across both groups with disabling symptoms (OR 0.84, 95% CI 0.38-1.88) and nondisabling symptoms (OR 0.82, 95% CI 0.66-1.03). The pooled analysis, which incorporated nonoverlapping subgroups and post hoc data, yielded consistent findings. DISCUSSION: The findings suggest that IVT does not confer improved functional outcomes among patients with minor strokes and can be associated with higher odds of sICH and mortality at 90 days compared with NT-SC. Since most of the included patients presented with nondisabling minor strokes, additional studies on patients with mildly disabling symptoms are warranted.
引用
- Doheim MF, Nguyen TN, Xiong Y, et al. Meta-Analysis of Randomized Controlled Trials on IV Thrombolysis in Patients With Minor Acute Ischemic Stroke. Neurology. 2025. PMID: 40674672. doi:10.1212/WNL.0000000000213863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。